| Immune thrombocytopenic purpura
Rayos vs Rhophylac
Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.Deep comparison between: Rayos vs Rhophylac with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRhophylac has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rhophylac but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Rhophylac
At A Glance
Oral
Daily
Corticosteroid
IV or IM injection
Single dose
Rh(D) immune globulin
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Rh Isoimmunization
- Immune thrombocytopenic purpura
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Rh Isoimmunization 300 mcg (1500 IU) IV or IM injection; routine antepartum prophylaxis at week 28-30 of pregnancy; postpartum and obstetric complication doses within 72 hours of event; for excessive fetomaternal hemorrhage (>15 mL fetal RBCs), 300 mcg plus 20 mcg per mL fetal RBCs in excess of 15 mL; for incompatible transfusions, 20 mcg per 2 mL Rh(D)-positive whole blood within 72 hours of exposure.
Immune thrombocytopenic purpura 50 mcg per kg body weight by IV route only, administered at a rate of 2 mL per 15 to 60 seconds.
Contraindications
- Known hypersensitivity to prednisone or any excipient
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity to RHOPHYLAC or any of its components
- Newborn infant of a mother who received RHOPHYLAC postpartum
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Most common - Rh Isoimmunization (>=0.5%) Nausea, dizziness, headache, injection-site pain, malaise
Most common - Immune thrombocytopenic purpura (>14%) Chills, pyrexia/increased body temperature, increased blood bilirubin, headache
Serious Intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, DIC (observed in ITP treatment)
Postmarketing Hypersensitivity reactions including anaphylactic shock, headache, dizziness, vertigo, hypotension, tachycardia, dyspnea, nausea, vomiting, rash, erythema, pruritus, chills, pyrexia, malaise, diarrhea, back pain
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Rh(D) immune globulin (anti-D) that suppresses immunization to Rh(D)-positive RBCs by accelerating their clearance; in ITP, forms Rh(D) immune globulin-RBC complexes preferentially removed by the reticuloendothelial system, causing Fc receptor blockade that spares antibody-coated platelets.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Rhophylac
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rhophylac
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Rhophylac
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
Cost estimate not availableAssistance Fund: Thrombocytopenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RhophylacView full Rhophylac profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.